Immunovant
IMVT
119 hedge funds and large institutions have $294M invested in Immunovant in 2021 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 41 increasing their positions, 40 reducing their positions, and 17 closing their positions.
1,278% more call options, than puts
Call options by funds: $47.9M | Put options by funds: $3.48M
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
8% more funds holding
Funds holding: 110 → 119 (+9)
3% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 40
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9.99% less ownership
Funds ownership: 39.36% → 29.38% (-10%)
28% less capital invested
Capital invested by funds: $408M → $294M (-$114M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$14.2M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10.3M |
| 3 |
AGM
Alpine Global Management
New York
|
+$9.02M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$5.01M |
| 5 |
FM
Frazier Management
Seattle,
Washington
|
+$2.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$31.7M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$13.5M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$10.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$7.59M |
| 5 |
OFCM
One Fin Capital Management
San Francisco,
California
|
-$6.47M |
IMVT Hedge Fund Activity: Q3 2021 in Review
119 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q3 2021, worth a combined $294M — down 28% from $408M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new IMVT positions and 17 closed out — a net gain of 9 holders — while 41 added to existing stakes and 40 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $14.2M. The largest seller was Woodline Partners, cutting an estimated $31.7M.
- 119 institutional investors held Immunovant (IMVT) as of Q3 2021, up from 110 in Q2 2021.
- Funds reported $294M of Immunovant stock for Q3 2021, down 28% quarter-over-quarter.
- 26 funds opened new Immunovant positions in Q3 2021 and 17 closed out, a net change of +9 holders.
- The largest Immunovant buyer in Q3 2021 was Eventide Asset Management, an estimated $14.2M added.
- The largest Immunovant seller in Q3 2021 was Woodline Partners, an estimated $31.7M sold.
Based on aggregated 13F filings for Q3 2021.